|
[1]
|
Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota[J]. Trans Am Ophthalmol Soc, 1994, 92:477-588. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=PubMed000001127181 |
|
[2]
|
Wiersinga WM, Smit T, van der Gaag R, et al. Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease[J]. J Endocrinol Invest, 1988, 11:615-619. doi: 10.1007/BF03350193 |
|
[3]
|
Bahn RS. Graves' ophthalmopathy[J]. N Engl J Med, 2010, 362:726-738. doi: 10.1056/NEJMra0905750 |
|
[4]
|
Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy[J]. Clin Endocrinol, 1997, 47:9-14. doi: 10.1046/j.1365-2265.1997.2331047.x |
|
[5]
|
Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO[J]. Eur J Endocrinol, 2008, 158:273-285. doi: 10.1530/EJE-07-0666 |
|
[6]
|
Smith TJ. Pathogenesis of Graves' orbitopathy:a 2010 update[J]. J Endocrinol Invest, 2010, 33:414-421. doi: 10.1007/BF03346614 |
|
[7]
|
Zang S, Ponto KA, Kahaly GJ. Clinical review:intravenous glucocorticoids for Graves' orbitopathy:efficacy and morbidity[J]. J Clin Endocrinol Metab, 2011, 96:320-332. doi: 10.1210/jc.2010-1962 |
|
[8]
|
Shams PN, Ma R, Pickles T, et al. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease[J]. Am J Ophthalmol, 2014, 157:1299-1305. doi: 10.1016/j.ajo.2014.02.044 |
|
[9]
|
Kazim M, Garrity JA. Orbital radiation therapy for thyroid eye disease[J]. J Neuroophthalmol, 2012, 32:172-176. doi: 10.1097/WNO.0b013e318255d7c7 |
|
[10]
|
Pillar AJ, Richa DC. Treatment options for thyroid eye disease[J]. Curr Treat Options Neurol, 2014, 16:303. doi: 10.1007/s11940-014-0303-8 |
|
[11]
|
Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for graves' orbitopathy[J]. J Clin Endocrinol Metab, 2013, 98:4291-4299. doi: 10.1210/jc.2013-1804 |
|
[12]
|
Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression[J]. Eur J Endocrinol, 2006, 154:511-517. doi: 10.1530/eje.1.02119 |
|
[13]
|
Mitchell AL, Gan EH, Morris M, et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy[J]. Clin Endocrinol, 2013, 79:437-442. doi: 10.1111/cen.12141 |
|
[14]
|
Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves' orbitopathy:A randomized controlled study[J]. J Clin Endocrinol Metab, 2015, 100:422-431. doi: 10.1210/jc.2014-3014 |
|
[15]
|
Savino G, Balia L, Colucci D, et al. Intraorbital injection of rituximab:A new approach for active thyroid-associated orbitopathy, a prospective case series[J]. Minerva Endocrinol, 2013, 38:173-179. http://www.ncbi.nlm.nih.gov/pubmed/23732371 |
|
[16]
|
Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial:metabolic and immunologic features at baseline identify a subgroup of responders[J]. Diabetes, 2013, 62:3766-3774. doi: 10.2337/db13-0345 |
|
[17]
|
Rossi D, Modena V, Sciascia S, et al. Pheumatoid arthritis:Biological therapy other than anti-TNF[J]. Int Immunopharmacol, 2015, 27:185-188. doi: 10.1016/j.intimp.2015.03.019 |
|
[18]
|
Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC. Treatment of active corticosteroid-resistant Graves' orbitopathy[J]. Ophthal Plast Reconstr Surg, 2014, 30:162-167. doi: 10.1097/IOP.0000000000000037 |
|
[19]
|
Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases[J]. Nat Rev Drug Discov, 2012, 11:633-652. doi: 10.1038/nrd3800 |
|
[20]
|
Tan GH, Dutton CM, Bahn RS. Interleukin-1(IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 1996, 81:449-452. http://www.ncbi.nlm.nih.gov/pubmed/8636247 |
|
[21]
|
Cawood TJ, Moriarty P, O'Farrelly C, et al. Smoking and thyroid-associated ophthalmopathy:A novel explanation of the biological link[J]. J Clin Endocrinol Metab, 2007, 92:59-64. doi: 10.1210/jc.2006-1824 |
|
[22]
|
Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease[J]. J Neuroophthalmol, 2014, 34:177-185. doi: 10.1097/WNO.0000000000000132 |
|
[23]
|
Durrani OM, Reuser TQ, Murray PI. Infliximab:A novel treatment for sight-threatening thyroid associated ophthalmopathy[J]. Orbit, 2005, 24:117-119. doi: 10.1080/01676830590912562 |
|
[24]
|
Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy:A pilot study[J]. Eye, 2005, 19:1286-1289. doi: 10.1038/sj.eye.6701768 |
|
[25]
|
Ayabe R, Rootman DB, Hwang CJ, et al. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease[J]. Ophthal Plastic Reconstr Surg, 2014, 30:415-419. doi: 10.1097/IOP.0000000000000211 |
|
[26]
|
van Steensel L, Paridaens D, van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 2012, 97:E400-E408. doi: 10.1210/jc.2011-2697 |
|
[27]
|
van Steensel L, Paridaens D, Schrijver B, et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts:A potential treatment for Graves' ophthalmopathy[J]. Invest Ophthalmol Vis Sci, 2009, 50:3091-3098. doi: 10.1167/iovs.08-2443 |
|
[28]
|
Viraku S, Dalm VASH, Paridaens D, et al. The tyrosine kinase inhibitor dasatinib efficiently blocks PDGF-induced orbital fibroblast activation[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252:1101-1109. doi: 10.1007/s00417-014-2674-7 |
|
[29]
|
Kriss JV, Pleshakov V, Rosenblum AL, et al. Studies on the pathogenesis of the ophthahmopathy of Graves' disease[J]. J Clin Endoerinol Metab, 1967, 27:582-593. doi: 10.1210/jcem-27-4-582 |
|
[30]
|
Kumar S, Coenen MJ, Scherer PE, et al. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 2004, 89:930-935. doi: 10.1210/jc.2003-031427 |
|
[31]
|
Neumann S, Pope A, Geras-Raaka E, et al. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts[J]. Thyroid, 2012, 22:839-843. doi: 10.1089/thy.2011.0520 |
|
[32]
|
Turcu AF, Kumar S, Neumann S, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy[J]. J Clin Endocrinol Metab, 2013, 98:2153-2159. doi: 10.1210/jc.2013-1149 |
|
[33]
|
Chen H, Mester T, Raychaudhuri N, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes[J]. J Clin Endocrinol Metab, 2014, 99:E1635-E1640. doi: 10.1210/jc.2014-1580 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
